Merino Trial Summary
Actual primary completion date.
Merino trial summary. Coli and klebsiella species. The merino trial offered to overcome some of the discrepancies seen in the previous studies. Merino trial this supplement contains the following items.
Susceptible escherichia coli and klebsiella spp. 11 this study was an international multicenter open label randomized noninferiority trial of ptz 45 g every 6 hours versus meropenem 1 g every 8 hours for the definitive treatment of e coli or k pneumoniae bloodstream infections resistant to ceftriaxone. Randomized controlled trial of meropenem versus piperacillin tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non susceptible e.
Actual study completion date. Findings in this noninferiority randomized clinical trial that included 391 patients with e coli or k pneumoniae bloodstream infection and ceftriaxone resistance the 30 day mortality rate for patients treated with piperacillin tazobactam compared with meropenem was 123 vs 37 respectively. The poet trial showed that oral antibiotics were noninferior to intravenous antibiotics at preventing adverse events.
The merino trial is the first randomized controlled trial to evaluate piperacillintazobactam versus meropenem for the definitive treatment of bsis caused by ceftriaxone not susceptible e coli or k pneumoniae that remained susceptible to piperacillintazobactam by current breakpoints. Original protocol final protocol summary of changes. Listing a study does not mean it has been evaluated by the us.
Save this study trial of meropenem versus piperacillin tazobactam on mortality and clinial response merino ii the safety and scientific validity of this study is the responsibility of the study sponsor and investigators. The merino trial is a landmark study published in september of 2018 that investigated piperacillin tazobactam versus meropenem for the treatment of bloodstream infection caused by ceftriaxone resistant e. Original statistical analysis plan final statistical analysis plan summary of changes.
Coli or klebsiella pneumoniae.